Document Detail

Management of rosiglitazone-induced edema: two case reports and a review of the literature.
MedLine Citation:
PMID:  12396745     Owner:  NLM     Status:  MEDLINE    
The thiazolidinediones are an important class of insulin-sensitizing agents used for the treatment of type 2 diabetes. Similar to other antidiabetic agents, use of the thiazolidinediones is limited by adverse drug reactions. Specifically, use of the thiazolidinediones is associated with a triad of fluid retention, edema, and weight gain. In premarketing clinical trials, edema was reported to occur infrequently with minimal severity. However, several published cases from postmarketing data demonstrate that thiazolidinedione-induced fluid retention, exhibited by the initial onset of peripheral edema and weight gain, can progress to a more severe form of pulmonary edema that is refractory to diuretic therapy with resolution of symptoms only through discontinuation of the offending thiazolidinedione. In clinical practice, the occurrence of edema secondary to a thiazolidinedione drug may occur more frequently than reported. Two cases presented in this report illustrate a different outpatient management approach that enables both desired glycemic control and minimal fluid retention while using the thiazolidinediones.
Fei Wang; Lauren M Aleksunes; Louise A Reagan; Cunegundo M Vergara
Related Documents :
2916765 - Augmented fragmentation of atrial activity upon premature electrical stimuli by verapamil.
14506815 - Revisiting anna o.: a case of chemical dependence.
2002185 - Soft tissue calcifications induced by local corticosteroid injection.
3325615 - Oligodendroglioma occurring after radiation therapy for pituitary adenoma.
8492575 - Role of serum markers for liver function and liver regeneration in the management of ch...
22953115 - Kikuchi-fujimoto disease: a case report and literature review.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  4     ISSN:  1520-9156     ISO Abbreviation:  Diabetes Technol. Ther.     Publication Date:  2002  
Date Detail:
Created Date:  2002-10-24     Completed Date:  2003-04-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  505-14     Citation Subset:  IM    
Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut 06269-2092, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Body Weight
Clinical Trials as Topic
Diabetes Mellitus / drug therapy*
Diabetes Mellitus, Type 2 / drug therapy*
Diuresis / drug effects*
Edema / chemically induced*,  therapy
Hemoglobin A, Glycosylated / metabolism
Hypoglycemic Agents / adverse effects*
Middle Aged
Thiazoles / adverse effects*
Reg. No./Substance:
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Thiazoles; 0/Thiazolidinediones; 122320-73-4/rosiglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ultrasound-assisted insulin delivery and noninvasive glucose sensing.
Next Document:  From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.